Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 352

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 352
---
 that some or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, including its net operating losses. Based on its history of operating losses, the Company believes that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of June 30, 2025, and December 31, 2024. Note 10-Stockholders’equity As of June 30, 2025, the Company had two classes of stock authorized in its Articles of Incorporation, as amended (the “Articles”). F-106

Common Stock The Company is authorized to issue up to 200,000,000shares of common stock pursuant to its Articles. Holders of common stock are entitled to one vote for each share of common stock. As of June 30, 2025, there were 49,913,946shares of common stock outstanding. Preferred Stock The Company is authorized to issue up to 5,000,000shares of Preferred Stock pursuant to its Articles. The historical Kintara Series A Preferred Stock were assumed in connection with the Kintara Merger and 278,530are outstanding and have a stated value of $ 278,530as of June 30, 2025, and December 31, 2024. Securities Purchase Agreement On June 2, 2025, the Company entered into the Securities Purchase Agreement with the Purchasers, pursuant to which the Company issued and sold an aggregate of 4,759,309shares of common stock and Warrants to purchase up to an aggregate of 4,759,309shares of common stock, at a combined effective offering price for each share and accompanying Warrant of $ 2.65. The Warrants have an exercise price of $ 3.3125per share and are exercisable beginning December 2, 2025, and will expire five years following the exercisable date. The Purchaser’s obligations to purchase the shares in the Offering were subject to four equal tranches pursuant to separate milestone closings set forth in the Securities Purchase Agreement, all of which were achieved on or before June 30, 2025. The Company received gross proceeds totaling $ 8,912,175from the sale of stock, which was fully received through August 14, 2025. In addition to the funds received in